摘要
目的探讨上皮细胞黏附分子（CD326）在乳腺癌细胞系中的表达及其与乳腺癌细胞耐药的关系。方法流式细胞仪分析MCF-7、MCF-7／ADR及MDA-MB-231中CD326表达情况；细胞计数法（CCK-8法）检测流式细胞仪分选获得的CD326阳性和阴性细胞亚群体外对表阿霉素、多西他赛耐药情况；逆转录-聚合酶链反应（RT-PCR）检测不同细胞亚群中多药耐药基因（MDR1）及乳腺相关耐药基因（BCRP）的表达情况。结果MCF-7／ADR中CD326的表达（31．03％）明显高于亲本株MCF-7（27．02％），MDA-MB-231中CD326的表达（33．43％）明显高于MCF-7及MCF-7／ADR；MCF-7和MDA-MB-231中CD326阳性细胞亚群对表阿霉素及低浓度多西他赛（0．25～1．0＊IC50）的体外耐受性明显高于阴性细胞亚群（P〈0．01），但对高浓度多西他赛（1．5～2．0＊IC50）的体外耐受性差异无统计学意义（P〉0．05）；CD326阳性与阴性细胞亚群间MDR1、BCRP基因表达差异无统计学意义（P〉0．05）。结论CD326与乳腺癌化疗药物的耐药有关，其诱导耐药并不是通过经典的耐药途径。
Objective To investigate the expression of CD326 among three breast carcinoma cell lines as well as their effect on chemotherapy drug resistance. Methods The expression of CD326 in MCF- 7, MCF-7/ADR and MDA-MB-231 was detected by flow cytometry. The resistance of epirubicin and docetaxel was determined by CCK-8 method in CD326^＋ cells and CD326-cells, respectively ,which were sorted by the flow cytometry. The MDR-1 and BCRP of different subsets were examinaed by RT-PCR. Results The expression levels of CD326 in MCF-7/ADR （ 31.03% ） were significantly higher than in MCF-7 （27.02%） ,but lower than in MDA-MB-231 （33.43%）. The statistical significance of resistance was obtained in all concentrations of epirubicin and lower concentration （0.25-1.0 ＊ IC50） of docetaxel （P 〈 0.01 ） , but not in higher concentration （ 1.5-2.0 ＊ IC50） of docetaxel （ P 〉 0.05 ） , between CD326^＋ cells and CD326-cells in MCF-7, MDA-MB-213, respectively,in vitro. There was no significant difference in the expression of MDR1 as well as BCRP between CD326^＋ and CD326-subsets （ P 〉 0. 05 ）. Conclusion The expression of CD326 in breast carcinoma cells induces the chemotherapy resistance of breast carcinoma not by classical ways.
出处
《中华实验外科杂志》
CAS
CSCD
北大核心
2008年第9期1155-1157,共3页
Chinese Journal of Experimental Surgery
基金
湖北省“十一五”科技攻关重大项目（S05-1）
